Do analysts recommend NBP or SCLX?

I-Mab presently has a consensus price target of $9.00, suggesting a potential upside of 447.11%. Given I-Mab's stronger consensus rating and higher probable upside, analysts plainly believe I-Mab is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, NBP or SCLX?

I-Mab has higher earnings, but lower revenue than Scilex. I-Mab is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 48.91 -$46.27M -$0.36 N/A Scilex $30.25M 1.96 -$358.73M -$40.47 N/A

Is NBP or SCLX more profitable?

I-Mab has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Scilex -1,110.17% N/A -143.55%

Does the media prefer NBP or SCLX?

In the previous week, Scilex had 1 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Scilex and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.44 beat Scilex's score of 0.00 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACB or SCLX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ACB or SCLX?

Aurora Cannabis has higher revenue and earnings than Scilex. Aurora Cannabis is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurora Cannabis $246.72M 0.84 $1.63M -$1.08 N/A Scilex $30.25M 1.96 -$358.73M -$40.47 N/A

Is ACB or SCLX more profitable?

Aurora Cannabis has a net margin of -23.46% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Aurora Cannabis' return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -23.46% -0.04% -0.03% Scilex -1,110.17% N/A -143.55%

Does the media refer more to ACB or SCLX?

In the previous week, Aurora Cannabis and Aurora Cannabis both had 3 articles in the media. Aurora Cannabis' average media sentiment score of 0.62 beat Scilex's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TNXP or SCLX?

Tonix Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential upside of 98.74%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer TNXP or SCLX?

In the previous week, Scilex had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Tonix Pharmaceuticals. Scilex's average media sentiment score of 0.00 beat Tonix Pharmaceuticals' score of -1.19 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Scilex 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARCT or SCLX?

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 3 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.18 beat Scilex's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RNAC or SCLX more profitable?

Scilex has a net margin of -1,110.17% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics -8,550.65% N/A -28.25% Scilex -1,110.17% N/A -143.55%

Scilex (SCLX) Competitors

$7.00 -0.58 (-7.65%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$6.92 -0.08 (-1.07%)

As of 06/5/2026 07:40 PM Eastern

Compare

SCLX vs. NBP, ACB, TNXP, ARCT, and RNAC

Should you buy Scilex stock or one of its competitors? MarketBeat compares Scilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scilex include I-Mab (NBP), Aurora Cannabis (ACB), Tonix Pharmaceuticals (TNXP), Arcturus Therapeutics (ARCT), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry.

How does Scilex compare to I-Mab?

I-Mab (NASDAQ:NBP) and Scilex (NASDAQ:SCLX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

In the previous week, Scilex had 1 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Scilex and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.44 beat Scilex's score of 0.00 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.4% of I-Mab shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 4.1% of Scilex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

I-Mab presently has a consensus price target of $9.00, suggesting a potential upside of 447.11%. Given I-Mab's stronger consensus rating and higher probable upside, analysts plainly believe I-Mab is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

I-Mab has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

I-Mab has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Scilex	-1,110.17%	N/A	-143.55%

I-Mab has higher earnings, but lower revenue than Scilex. I-Mab is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	48.91	-$46.27M	-$0.36	N/A
Scilex	$30.25M	1.96	-$358.73M	-$40.47	N/A

Summary

I-Mab beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Scilex compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Aurora Cannabis has higher revenue and earnings than Scilex. Aurora Cannabis is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$246.72M	0.84	$1.63M	-$1.08	N/A
Scilex	$30.25M	1.96	-$358.73M	-$40.47	N/A

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 4.1% of Scilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aurora Cannabis has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Scilex has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Aurora Cannabis has a net margin of -23.46% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-23.46%	-0.04%	-0.03%
Scilex	-1,110.17%	N/A	-143.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aurora Cannabis and Aurora Cannabis both had 3 articles in the media. Aurora Cannabis' average media sentiment score of 0.62 beat Scilex's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aurora Cannabis beats Scilex on 8 of the 14 factors compared between the two stocks.

How does Scilex compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Tonix Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Scilex has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Tonix Pharmaceuticals currently has a consensus target price of $22.00, suggesting a potential upside of 98.74%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tonix Pharmaceuticals has a net margin of -839.52% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Scilex	-1,110.17%	N/A	-143.55%

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Scilex had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Scilex and 1 mentions for Tonix Pharmaceuticals. Scilex's average media sentiment score of 0.00 beat Tonix Pharmaceuticals' score of -1.19 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tonix Pharmaceuticals has higher earnings, but lower revenue than Scilex. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	13.46	-$124.02M	-$14.36	N/A
Scilex	$30.25M	1.96	-$358.73M	-$40.47	N/A

Summary

Tonix Pharmaceuticals beats Scilex on 9 of the 16 factors compared between the two stocks.

How does Scilex compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Arcturus Therapeutics has a net margin of -143.80% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Scilex	-1,110.17%	N/A	-143.55%

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 4.1% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 3 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.18 beat Scilex's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcturus Therapeutics currently has a consensus target price of $25.44, indicating a potential upside of 248.55%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Arcturus Therapeutics has higher revenue and earnings than Scilex. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.53	-$65.78M	-$2.81	N/A
Scilex	$30.25M	1.96	-$358.73M	-$40.47	N/A

Arcturus Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market. Comparatively, Scilex has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Scilex on 14 of the 16 factors compared between the two stocks.

How does Scilex compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Cartesian Therapeutics presently has a consensus target price of $32.60, suggesting a potential upside of 458.22%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cartesian Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Scilex has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

In the previous week, Scilex had 3 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Scilex and 0 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.00 equaled Scilex'saverage media sentiment score.

Company	Overall Sentiment
Cartesian Therapeutics	Neutral
Scilex	Neutral

Scilex has a net margin of -1,110.17% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
Scilex	-1,110.17%	N/A	-143.55%

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 37.2% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 4.1% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cartesian Therapeutics has higher earnings, but lower revenue than Scilex. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	61.28	-$130.30M	-$5.90	N/A
Scilex	$30.25M	1.96	-$358.73M	-$40.47	N/A

Summary

Cartesian Therapeutics beats Scilex on 9 of the 14 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLX vs. The Competition

Export

Metric	Scilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$59.44M	$3.34B	$6.68B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-0.17	10.33	20.29	21.86
Price / Sales	1.96	300.34	519.33	112.45
Price / Cash	N/A	116.33	42.23	54.60
Price / Book	-0.28	6.51	9.73	6.35
Net Income	-$358.73M	$24.19M	$3.57B	$337.59M
7 Day Performance	-21.35%	-6.96%	-1.26%	-2.51%
1 Month Performance	-26.32%	-4.27%	0.82%	-0.69%
1 Year Performance	10.94%	36.81%	24.09%	25.37%

Scilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLX Scilex	0.4512 of 5 stars	$7.00 -7.7%	N/A	+8.2%	$59.44M	$30.25M	N/A	80	News Coverage Gap Up
NBP I-Mab	2.6633 of 5 stars	$1.77 flat	$9.00 +408.5%	N/A	$204.70M	$3.89M	N/A	380
ACB Aurora Cannabis	0.9373 of 5 stars	$3.46 flat	N/A	-37.5%	$204.51M	$246.72M	N/A	1,130	Upcoming Earnings
TNXP Tonix Pharmaceuticals	3.5982 of 5 stars	$12.77 flat	$22.00 +72.3%	-71.2%	$203.57M	$13.11M	N/A	50	Negative News
ARCT Arcturus Therapeutics	2.5448 of 5 stars	$7.03 flat	$25.44 +261.9%	-38.7%	$199.81M	$82.03M	N/A	180	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scilex (SCLX) Competitors

SCLX vs. NBP, ACB, TNXP, ARCT, and RNAC

How does Scilex compare to I-Mab?

Summary

How does Scilex compare to Aurora Cannabis?

Summary

How does Scilex compare to Tonix Pharmaceuticals?

Summary

How does Scilex compare to Arcturus Therapeutics?

Summary

How does Scilex compare to Cartesian Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scilex (SCLX) Competitors

SCLX vs. NBP, ACB, TNXP, ARCT, and RNAC

How does Scilex compare to I-Mab?

Does the media prefer NBP or SCLX?

Do insiders & institutionals hold more shares of NBP or SCLX?

Do analysts recommend NBP or SCLX?

Which has more risk and volatility, NBP or SCLX?

Is NBP or SCLX more profitable?

Which has preferable earnings and valuation, NBP or SCLX?

Summary

How does Scilex compare to Aurora Cannabis?

Which has stronger earnings and valuation, ACB or SCLX?

Do institutionals and insiders have more ownership in ACB or SCLX?

Which has more risk and volatility, ACB or SCLX?

Is ACB or SCLX more profitable?

Do analysts prefer ACB or SCLX?

Does the media refer more to ACB or SCLX?

Summary

How does Scilex compare to Tonix Pharmaceuticals?

Which has more volatility and risk, TNXP or SCLX?

Do analysts rate TNXP or SCLX?

Is TNXP or SCLX more profitable?

Do institutionals & insiders have more ownership in TNXP or SCLX?

Does the media prefer TNXP or SCLX?

Which has better valuation and earnings, TNXP or SCLX?

Summary

How does Scilex compare to Arcturus Therapeutics?

Is ARCT or SCLX more profitable?

Do insiders and institutionals believe in ARCT or SCLX?

Does the media refer more to ARCT or SCLX?

Do analysts prefer ARCT or SCLX?

Which has higher earnings & valuation, ARCT or SCLX?

Which has more volatility and risk, ARCT or SCLX?

Summary

How does Scilex compare to Cartesian Therapeutics?

Do analysts recommend RNAC or SCLX?

Which has more risk & volatility, RNAC or SCLX?

Does the media refer more to RNAC or SCLX?

Is RNAC or SCLX more profitable?

Do institutionals and insiders hold more shares of RNAC or SCLX?

Which has preferable earnings & valuation, RNAC or SCLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools